Literature DB >> 32291830

Scalable Total Syntheses and Structure-Activity Relationships of Haouamine A, B, and their Derivatives as Stable Formate Salts.

Hirokazu Tsukamoto1, Saki Nakamura2, Akito Tomida2, Doi Takayuki2.   

Abstract

Haouamines A, B, and their derivatives were synthesized via Suzuki-Miyaura coupling and three key cyclization reactions as follows: the newly developed palladium(0)-catalyzed arylative cyclization of phenylalanine-derived alkyne-aldehydes with 2-bromoarylboronic acid (an 'anti-Wacker'-type cyclization); BF3·OEt2-promoted Friedel-Crafts-type cyclization of symmetrical electron-rich aromatic rings adjacent to a tertiary allylic alcohol leading to the indeno-tetrahydropyridine skeleton; and (cyanomethyl)trimethylphosphonium iodide-mediated macrocyclization of amino alcohols to afford aza-paracyclophane precursors. The palladium-catalyzed reduction of mono- and di-triflate intermediates in the later stages enabled the alteration of both the position and number of hydroxyl groups on the C-ring. The instability of haouamine B was dramatically improved by salt formation with formic acid. An unambiguous evaluation of the cytotoxicity of the prepared haouamine derivative formates with and without hydroxyl groups at different positions on the C-ring indicated that the catechol structure in haouamine B produced weak cytotoxicity.
© 2020 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim.

Entities:  

Keywords:  'anti-Wacker'-type cyclization; Friedel-Crafts-type cyclization; haouamine; macrocyclization of amino alcohol; structure-activity relationship

Year:  2020        PMID: 32291830     DOI: 10.1002/chem.202001756

Source DB:  PubMed          Journal:  Chemistry        ISSN: 0947-6539            Impact factor:   5.236


  1 in total

1.  Soft Enolization of 3-Substituted Cycloalkanones Exhibits Significantly Improved Regiocontrol vs Hard Enolization Conditions.

Authors:  Natalie C Dwulet; Vincenzo Ramella; Christopher D Vanderwal
Journal:  Org Lett       Date:  2021-12-06       Impact factor: 6.005

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.